Oscar Health, Inc. (NYSE:OSCR – Get Free Report) insider Janet Liang sold 7,338 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $16.59, for a total value of $121,737.42. Following the completion of the sale, the insider directly owned 172,527 shares of the company’s stock, valued at $2,862,222.93. The trade was a 4.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Oscar Health Stock Down 0.4%
NYSE:OSCR traded down $0.06 on Friday, hitting $17.12. The stock had a trading volume of 405,988 shares, compared to its average volume of 14,529,313. The company has a quick ratio of 0.92, a current ratio of 0.92 and a debt-to-equity ratio of 0.67. Oscar Health, Inc. has a 52 week low of $11.20 and a 52 week high of $23.80. The business’s fifty day moving average is $18.06 and its 200 day moving average is $16.94. The company has a market cap of $4.53 billion, a PE ratio of -15.31 and a beta of 1.88.
Oscar Health (NYSE:OSCR – Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.02. Oscar Health had a negative return on equity of 21.50% and a negative net margin of 2.16%.The firm had revenue of $2.93 billion during the quarter, compared to the consensus estimate of $3.09 billion. During the same quarter in the previous year, the company posted ($0.22) earnings per share. The company’s quarterly revenue was up 23.2% on a year-over-year basis. On average, equities research analysts expect that Oscar Health, Inc. will post 0.69 EPS for the current fiscal year.
Institutional Investors Weigh In On Oscar Health
Analysts Set New Price Targets
A number of research firms have weighed in on OSCR. Zacks Research raised shares of Oscar Health from a “strong sell” rating to a “hold” rating in a research note on Monday, October 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Oscar Health in a research note on Wednesday, October 8th. Piper Sandler raised Oscar Health from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $13.00 to $25.00 in a research note on Tuesday, November 25th. Wall Street Zen upgraded Oscar Health from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Finally, Wells Fargo & Company decreased their price target on Oscar Health from $14.00 to $11.00 and set an “underweight” rating for the company in a report on Thursday, November 13th. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat, Oscar Health currently has a consensus rating of “Reduce” and an average price target of $14.86.
Check Out Our Latest Stock Report on Oscar Health
About Oscar Health
Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.
Featured Articles
- Five stocks we like better than Oscar Health
- Buy P&G Now, Before It Sets A New All-Time High
- Salesforce Stock Is Coiled Like a Spring and Ready to Rebound
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Marvell’s Rally Extends: Data Centers and AMZN Chips Boost Shares
- Stock Market Upgrades: What Are They?
- Could Ross Stores Stock Hit $200 by Christmas? Here Are 3 Reasons Analysts Think So
Receive News & Ratings for Oscar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oscar Health and related companies with MarketBeat.com's FREE daily email newsletter.
